[144] Alnylam Pharmaceuticals, Inc. SEC Filing
Form 144 filing for Alnylam Pharmaceuticals (ALNY) discloses a proposed sale of 3,474 shares of Common stock through UBS Financial Services on NASDAQ with an aggregate market value of $1,571,012 and 131,079,015 shares outstanding. The securities were acquired as performance stock units: 1,673 shares on 06/24/2024 and 1,801 shares on 04/26/2023, with payment dates matching acquisition dates. The filer reports Nothing to Report for securities sold in the past three months and includes the customary representation that they do not possess undisclosed material adverse information. The notice is procedural under Rule 144 to report an intended sale.
Deposito del Modulo 144 per Alnylam Pharmaceuticals (ALNY) indica una proposta di vendita di 3.474 azioni ordinarie tramite UBS Financial Services sul NASDAQ con un valore di mercato complessivo di $1.571.012 e 131.079.015 azioni in circolazione. I titoli sono stati acquisiti come performance stock units: 1.673 azioni il 24/06/2024 e 1.801 azioni il 26/04/2023, con date di pagamento corrispondenti alle date di acquisizione. Il dichiarante segnala Nessuna informazione da comunicare riguardo a titoli venduti negli ultimi tre mesi e include la consueta dichiarazione di non possedere informazioni materiali avverse non divulgate. L'avviso 猫 di natura procedurale ai sensi della Regola 144 per segnalare una vendita prevista.
Presentaci贸n del Formulario 144 para Alnylam Pharmaceuticals (ALNY) revela una propuesta de venta de 3.474 acciones ordinarias a trav茅s de UBS Financial Services en el NASDAQ con un valor de mercado agregado de $1.571.012 y 131.079.015 acciones en circulaci贸n. Los t铆tulos fueron adquiridos como unidades de acciones por desempe帽o: 1.673 acciones el 24/06/2024 y 1.801 acciones el 26/04/2023, con fechas de pago coincidentes con las de adquisici贸n. El declarante informa Nada que reportar sobre valores vendidos en los 煤ltimos tres meses e incluye la representaci贸n habitual de no poseer informaci贸n material adversa no divulgada. El aviso es de car谩cter procedimental bajo la Regla 144 para comunicar una venta prevista.
Alnylam Pharmaceuticals (ALNY) 甏�霠� Form 144 鞝滌稖鞚� UBS Financial Services毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 3,474欤茧ゼ 毵る弰頃� 瓿勴殟鞚� 瓿店皽頃橂┌, 齑� 鞁滌灔 臧�旃� $1,571,012鞕赌 131,079,015欤检潣 氚滍枆 欤检嫕 靾橂ゼ 氤搓碃頃╇媹雼�. 頃措嫻 歃濌秾鞚� 靹标臣 欤检嫕 雼渼搿� 旆摑霅橃棃鞙茧┌: 2024-06-24鞐� 1,673欤�, 2023-04-26鞐� 1,801欤茧ゼ 旆摑頄堦碃 歆�旮夓澕鞚� 旆摑鞚缄臣 鞚检箻頃╇媹雼�. 鞝滌稖鞚胳潃 歆�雮� 3臧滌洈 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚� 氤搓碃頃橁碃 鞛堨溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 韱奠儊鞝侅溂搿� 歆勳垹頃橁碃 鞛堨姷雼堧嫟. 鞚� 韱奠電� 鞓堨爼霅� 毵る弰毳� 氤搓碃頃橁赴 鞙勴暅 Rule 144鞐� 霐半ジ 鞝堨皑鞝� 韱奠鞛呺媹雼�.
D茅p么t du formulaire 144 pour Alnylam Pharmaceuticals (ALNY) r茅v猫le une vente propos茅e de 3 474 actions ordinaires via UBS Financial Services sur le NASDAQ, avec une valeur de march茅 globale de 1 571 012 $ et 131 079 015 actions en circulation. Les titres ont 茅t茅 acquis sous forme de performance stock units : 1 673 actions le 24/06/2024 et 1 801 actions le 26/04/2023, les dates de paiement correspondant aux dates d'acquisition. Le d茅clarant indique Rien 脿 d茅clarer concernant des titres vendus au cours des trois derniers mois et inclut la d茅claration habituelle de ne pas d茅tenir d'informations d茅favorables significatives non divulgu茅es. L'avis est de nature proc茅durale en vertu de la R猫gle 144 pour signaler une vente envisag茅e.
Formular 144-Einreichung f眉r Alnylam Pharmaceuticals (ALNY) offenbart einen geplanten Verkauf von 3.474 Stammaktien 眉ber UBS Financial Services an der NASDAQ mit einem gesamten Marktwert von $1.571.012 und 131.079.015 ausstehenden Aktien. Die Wertpapiere wurden als Performance-Stock-Units erworben: 1.673 Aktien am 24.06.2024 und 1.801 Aktien am 26.04.2023, wobei die Auszahlungsdaten den Erwerbsdaten entsprechen. Der Meldende gibt nichts zu melden bez眉glich in den letzten drei Monaten verkaufter Wertpapiere an und enth盲lt die 眉bliche Erkl盲rung, dass keine unver枚ffentlichten, wesentlichen nachteiligen Informationen vorliegen. Die Mitteilung ist prozedural gem盲脽 Regel 144, um einen beabsichtigten Verkauf zu melden.
- Clear disclosure of broker, planned sale date, share count, and aggregate market value
- Securities were acquired as PSUs, indicating compensation origin rather than third-party transfer
- No reported sales in the prior three months, simplifying aggregation rules
- Filer attests to absence of undisclosed material adverse information, consistent with Rule 144 requirements
- None.
Insights
TL;DR: Routine insider notice; small share sale relative to float, unlikely to materially affect company valuation.
The Form 144 reports a planned sale of 3,474 common shares valued at $1.57M. Versus 131.08M shares outstanding this position is immaterial to capital structure or market liquidity. The shares were issued as PSUs in 2023 and 2024, indicating compensation-related disposition rather than operational or strategic changes. Because no sales occurred in the prior three months and the filer attests to no undisclosed material information, this is a standard disclosure event and presents limited informational impact for investors.
TL;DR: Filing appears procedurally compliant with Rule 144 and includes required attestations; no red flags in the disclosed fields.
The notice identifies broker, planned sale date, share counts, acquisition dates and nature of acquisition (PSU). It states no reportable sales in the past three months and contains the signers representation about material nonpublic information. Absent contradictory data, the filing meets disclosure requirements and signals adherence to insider-sale reporting protocols. No compliance irregularities are evident from the provided content.
Deposito del Modulo 144 per Alnylam Pharmaceuticals (ALNY) indica una proposta di vendita di 3.474 azioni ordinarie tramite UBS Financial Services sul NASDAQ con un valore di mercato complessivo di $1.571.012 e 131.079.015 azioni in circolazione. I titoli sono stati acquisiti come performance stock units: 1.673 azioni il 24/06/2024 e 1.801 azioni il 26/04/2023, con date di pagamento corrispondenti alle date di acquisizione. Il dichiarante segnala Nessuna informazione da comunicare riguardo a titoli venduti negli ultimi tre mesi e include la consueta dichiarazione di non possedere informazioni materiali avverse non divulgate. L'avviso 猫 di natura procedurale ai sensi della Regola 144 per segnalare una vendita prevista.
Presentaci贸n del Formulario 144 para Alnylam Pharmaceuticals (ALNY) revela una propuesta de venta de 3.474 acciones ordinarias a trav茅s de UBS Financial Services en el NASDAQ con un valor de mercado agregado de $1.571.012 y 131.079.015 acciones en circulaci贸n. Los t铆tulos fueron adquiridos como unidades de acciones por desempe帽o: 1.673 acciones el 24/06/2024 y 1.801 acciones el 26/04/2023, con fechas de pago coincidentes con las de adquisici贸n. El declarante informa Nada que reportar sobre valores vendidos en los 煤ltimos tres meses e incluye la representaci贸n habitual de no poseer informaci贸n material adversa no divulgada. El aviso es de car谩cter procedimental bajo la Regla 144 para comunicar una venta prevista.
Alnylam Pharmaceuticals (ALNY) 甏�霠� Form 144 鞝滌稖鞚� UBS Financial Services毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 3,474欤茧ゼ 毵る弰頃� 瓿勴殟鞚� 瓿店皽頃橂┌, 齑� 鞁滌灔 臧�旃� $1,571,012鞕赌 131,079,015欤检潣 氚滍枆 欤检嫕 靾橂ゼ 氤搓碃頃╇媹雼�. 頃措嫻 歃濌秾鞚� 靹标臣 欤检嫕 雼渼搿� 旆摑霅橃棃鞙茧┌: 2024-06-24鞐� 1,673欤�, 2023-04-26鞐� 1,801欤茧ゼ 旆摑頄堦碃 歆�旮夓澕鞚� 旆摑鞚缄臣 鞚检箻頃╇媹雼�. 鞝滌稖鞚胳潃 歆�雮� 3臧滌洈 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚� 氤搓碃頃橁碃 鞛堨溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 韱奠儊鞝侅溂搿� 歆勳垹頃橁碃 鞛堨姷雼堧嫟. 鞚� 韱奠電� 鞓堨爼霅� 毵る弰毳� 氤搓碃頃橁赴 鞙勴暅 Rule 144鞐� 霐半ジ 鞝堨皑鞝� 韱奠鞛呺媹雼�.
D茅p么t du formulaire 144 pour Alnylam Pharmaceuticals (ALNY) r茅v猫le une vente propos茅e de 3 474 actions ordinaires via UBS Financial Services sur le NASDAQ, avec une valeur de march茅 globale de 1 571 012 $ et 131 079 015 actions en circulation. Les titres ont 茅t茅 acquis sous forme de performance stock units : 1 673 actions le 24/06/2024 et 1 801 actions le 26/04/2023, les dates de paiement correspondant aux dates d'acquisition. Le d茅clarant indique Rien 脿 d茅clarer concernant des titres vendus au cours des trois derniers mois et inclut la d茅claration habituelle de ne pas d茅tenir d'informations d茅favorables significatives non divulgu茅es. L'avis est de nature proc茅durale en vertu de la R猫gle 144 pour signaler une vente envisag茅e.
Formular 144-Einreichung f眉r Alnylam Pharmaceuticals (ALNY) offenbart einen geplanten Verkauf von 3.474 Stammaktien 眉ber UBS Financial Services an der NASDAQ mit einem gesamten Marktwert von $1.571.012 und 131.079.015 ausstehenden Aktien. Die Wertpapiere wurden als Performance-Stock-Units erworben: 1.673 Aktien am 24.06.2024 und 1.801 Aktien am 26.04.2023, wobei die Auszahlungsdaten den Erwerbsdaten entsprechen. Der Meldende gibt nichts zu melden bez眉glich in den letzten drei Monaten verkaufter Wertpapiere an und enth盲lt die 眉bliche Erkl盲rung, dass keine unver枚ffentlichten, wesentlichen nachteiligen Informationen vorliegen. Die Mitteilung ist prozedural gem盲脽 Regel 144, um einen beabsichtigten Verkauf zu melden.
FAQ
What does the Form 144 for ALNY disclose about the proposed sale?
How many shares outstanding does Alnylam report in the Form 144?
When and how were the shares to be sold acquired according to the filing?
Does the filer report any securities sold in the past three months for ALNY?
Who is the broker handling the proposed sale in this Form 144?
